Taysha Gene Therapies Stock (NASDAQ: TSHA)

Taysha Gene Therapies (NASDAQ:TSHA) Stock, Quote.Headers.trade-ideas

Taysha Gene Therapies

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Image 4

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

APTV

Larimar Therapeutics, Inc. - Common Stock

LRMR

TSHA

Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

Wall Street, US stocks

Eurozone

Commodities

Intraday Update

ASNS

CMTL

CRMT

DMTK

QMCO

RELI

S&amp;P 500 Edges Higher; America&#39;s Car-Mart Shares Tumble After Q4 Earnings

ALAR

AMIX

AWIN

AZTR

CABA

CHGG

CHWY

CVAC

ELWS

GERN

KARO

KAVL

Kintara Therapeutics, Inc. - Common Stock

KTRA

MBIO

MESA

MYND

NGNE

NLSP

NVAX

PDCO

PSNY

RKLB

SCNI

SILK

SKYE

SNOA

SVMH

SYNX

TOST

TRNR

VRPX

ZNTL

Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies Inc

WIIM

KB Home shares are trading lower following Q3 financial results.

Fulcrum expects to incur one-time costs of approximately $2.0 million in connection with this workforce reduction, primarily related to cash payments for severance.
The Company communicated the workforce reduction on September 24, 2024, and expects the majority of the costs associated with the reduction to be incurred during the third quarter ending September 30, 2024.
The workforce reduction is expected to result in annual operating expense savings of approximately $10.0 million beginning in the first quarter of 2025.

FULC

Fulcrum Plans To Reduce Its Workforce From 80 To 51 Full-time Employees; Expects Workforce Reduction To Result In Annual Operating Expense Savings Of $10M Beginning In Q1 Of 2025 - Filing

Guidance

KB Home Sees FY24 Housing Revenue $6.85B-$6.95B, Average Selling Price Around $490,000, Homebuilding Operating Income Margin Expected at 11.1%-11.2%

Offerings

Huntsman International Files For Offering Of $350M 5.700% Senior Notes Due 2034

Paul Kasowski, Who Has Served as Chief Compliance and Transformation Officer, Named New Chief Financial Officer
The Board of Directors Has Retained Independent Advisors to Support an Investigation Into Financial Reporting for Fiscal Years 2020-2023
SCOTTSDALE, Ariz., Sept. 24, 2024 (GLOBE NEWSWIRE) -- AMMO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWW#NASDAQ">POWW</a>, POWWP)))) ("AMMO" or the "Company"), the owner of&nbsp;GunBroker.com, the largest online marketplace serving the firearms and shooting sports industries, and a leading vertically integrated producer of high-performance ammunition and components,&nbsp;today announced that Paul Kasowski, who has served as the Company's Chief Compliance and Transformation Officer, has been appointed by AMMO's Board of Directors (the "Board") as the Company's new Chief Financial Officer, effective immediately. Mr. Kasowski succeeds Rob Wiley, who resigned on September 19, 2024 at the request of the Board.
After due consideration, the Company's Board determined that Mr. Kasowski possesses the requisite experience and qualifications to serve as CFO. Mr. Kasowski most recently served as Chief Compliance and Transformation Officer since January 2024.

Management

POWW

AMMO, Inc. Appoints Paul Kasowski As New Chief Financial Officer And Provides Corporate Update; The Board Of Directors Has Retained Independent Advisors To Support An Investigation Into Financial Reporting For Fiscal Years 2020-2023

KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) reported quarterly earnings of $2.04 per share which beat the analyst consensus estimate of $2.02 by 0.99 percent. The company reported quarterly sales of $1.750 billion which beat the analyst consensus estimate of $1.728 billion by 1.29 percent. This is a 10.27 percent increase over sales of $1.587 billion the same period last year.

Earnings

Earnings Beats

KB Home Q3 2024 GAAP EPS $2.04 Beats $2.02 Estimate, Sales $1.75B Beat $1.728B Estimate

PRZO

ParaZero Technologies shares are trading higher after the company announced it received a $187K purchase order from a US-based advanced air mobility company in the aerial vehicle industry.

-Metabolomics Diagnostics, a deep-tech machine learning diagnostic platform developer, has developed an innovative test, PrePsia, to accurately predict the risk of preeclampsia in pregnant women- &nbsp;
-The PrePsia test can predict preeclampsia risk as early as in the 12th week of pregnancy, allowing for early interventions to prevent serious health issues for mothers and their babies-
-PrepSia will be commercialized in the U.S. market in 2025 through Trinity Biotech's New York-based Immco reference laboratory-
DUBLIN, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has acquired privately held Metabolomics Diagnostics, an Irish deep-tech company, specialized in the development of novel biomarker-based diagnostic solutions for complex diseases. The deal values Metabolomics Diagnostics with an enterprise value of approximately $1.3 million with the consideration consisting of just over 270,000 Trinity Biotech plc's ADS with the balance of consideration being in cash and the assumption of liabilities.
This acquisition provides Trinity Biotech with a strategically important deep-tech platform of mass spectrometry combined with machine learning powered bioinformatics. Trinity Biotech will initially leverage its New York State-based Immco reference laboratory to rapidly commercialise the PrePsia test in the U.S. market, while examining the launch of this test in international markets. This technology platform represents another long-term growth driver alongside Trinity Biotech's continuous glucose monitoring (CGM) technology.

TRIB

Trinity Biotech's Deal Values Metabolomics Diagnostics With An Enterprise Value Of ~$1.3M With The Consideration Consisting Of Just Over 270,000 Trinity Biotech's ADS With The Balance Of Consideration Being In Cash And The Assumption Of Liabilities

Caroline Ellison, the former CEO of Alameda Research and a <a href="https://www.benzinga.com/markets/cryptocurrency/23/10/35168021/caroline-ellison-points-finger-at-ftxs-sam-bankman-fried-in-crypto-fraud-trial">central figure in the downfall of FTX</a>, has been sentenced to 24 months in Manhattan federal court on Tuesday.
What Happened: Once a trusted ally and romantic partner of FTX founder Sam Bankman-Fried, Ellison's cooperation with prosecutors played a crucial role in securing his conviction in the $8 billion fraud case.
Judge Lewis Kaplan, praised Ellison for her cooperation but said there cannot be a get out of jail free card and sentenced Ellison to 24 months at a minimum security facility, Bloomberg <a href="https://www.bloomberg.com/news/live-blog/2024-09-24/caroline-ellison-sentencing">reported</a>. Ellison also has to forfeit about $11 billion.
Why It Matters: Alameda Research, the hedge fund Ellison led, was tightly intertwined with FTX, the cryptocurrency exchange valued at $32 billion <a href="https://www.benzinga.com/markets/cryptocurrency/23/10/35445270/the-true-cost-of-the-ftx-collapse-how-much-did-sam-bankman-fried-really-make">before its collapse</a>.
FTX's downfall was tied to revelations of a scheme where billions in customer funds were secretly used to cover Alameda's risky trades and lavish expenditures. 
As a result, both firms crumbled, leaving customers and creditors in the lurch.
Ellison, who pleaded guilty to seven charges including wire fraud and money laundering, became a <a href="https://www.benzinga.com/markets/cryptocurrency/23/10/35169634/caroline-ellison-drops-bombshell-bankman-fried-wanted-to-be-president">key witness for the prosecution</a>.
During Bankman-Fried's trial, she admitted to engaging in fraudulent activities under his direction, notably misusing FTX customer <a href="https://www.benzinga.com/markets/cryptocurrency/23/10/35226787/caroline-ellison-testifies-on-ftxs-complex-financial-practices-in-bankman-frieds-ongoing-t">funds without their consent</a>.
Her testimony painted a detailed picture of Bankman-Fried's influence and shifted much of the blame for the collapse onto him.
Judge Lewis Kaplan also oversaw Bankman-Fried's trial and <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37988324/sam-bankman-fried-sentenced-to-25-years-judge-points-to-ambition-political-manipulation#:~:text=Ultimately%2C%20Kaplan%20sentenced%20Bankman%2DFried,the%20eyes%20of%20the%20public.">sentenced him to 25 years in prison</a>.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41011761/former-coinbase-cto-balaji-srinivasan-says-bitcoin-is-about-stopping-the-state-from-slowly">Former Coinbase CTO Balaji Srinivasan Says Bitcoin Is About Stopping The State From Slowly Draining Your Wealth</a>
Prosecutors lauded her cooperation, describing it as "exemplary" in court filings and refraining from recommending a specific sentence.
Her legal team has requested three years of supervised release without prison time, citing her substantial assistance in the case and the intense public scrutiny she has faced since the FTX collapse.
Ellison's cooperation came at a personal cost. 
In addition to media attention around the trial, her relationship with Bankman-Fried and her personal writings—leaked by Bankman-Fried to the New York Times—became tabloid fodder. 
Her private diary entries revealed feelings of self-doubt about leading Alameda and internal struggles over her relationship with Bankman-Fried, adding to the media storm that followed the FTX scandal.
Prosecutors acknowledged the unique challenges Ellison faced, stating, "The Government cannot think of another cooperating witness in recent history who has received a greater level of attention and harassment." 
Despite the intense scrutiny, her testimony was invaluable in bringing the <a href="https://www.benzinga.com/markets/cryptocurrency/23/10/35199443/caroline-ellison-reveals-manipulated-alameda-balance-sheets-in-bankman-fried-trial">facts of the FTX case to light</a>.
As the cryptocurrency industry continues to grapple with the fallout from FTX's implosion, the focus on safeguarding user funds and maintaining transparency is stronger than ever. 
Ellison's sentencing may serve as a reminder of the need for stricter oversight in the industry, especially as digital assets gain more mainstream attention.
What&#8217;s Next: In light of these developments, the upcoming Benzinga <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19 will be a crucial gathering for leaders in the crypto space to discuss the future of the industry and how to prevent such catastrophic failures from occurring again.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41009150/gary-gensler-led-sec-moved-forward-with-enforcing-crypto-regulation-despite-legal-problems">Gary Gensler-Led SEC Moved Forward With Enforcing Crypto Regulation &#8216;Despite Legal Problems,&#8217; Commissioner Admits In Hearing</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

From CEO To Inmate: Caroline Ellison Sentenced To 24 Months In FTX Case—What The Industry Must Learn

SFIX

Stitch Fix shares are trading lower after the company reported worse-than-expected Q4 EPS results.

Trinity Biotech Announces Acquisition Of Metabolomics Diagnostics, Co Has Developed An Innovative Test, PrePsia, To Accurately Predict The Risk Of Preeclampsia In Pregnant Women

According to the Schedule 13D amendment filed yesterday with the U.S. Securities and Exchange Commission disclosing the proposal,&nbsp;Danone beneficially owns approximately&nbsp;23.4%&nbsp;of Lifeway&#39;s outstanding common stock.
Lifeway shareholders do not need to take any action at this time.&nbsp;

LWAY

Lifeway Foods Confirms Receipt Of $25.00 Per Share Cash, Non-binding Proposal From Danone North America

Stitch Fix Sees FY25 Revenue $1.11B-$1.16B

Stitch Fix Sees Q1 Revenue $303M-$310M

According to a recent survey, <a href="https://www.benzinga.com/news/24/09/40912191/harris-walz-campaign-targeted-by-russian-hackers-microsoft-threat-analysis-center-notices-shift-in-t">cybersecurity threats</a> are business owners&#8217; top concern.
Almost two-thirds—62%—say they worry some or a great deal about cyber risks, according to The Travelers Companies&#8217; 2024 Travelers Risk Index, released on Tuesday.
"The findings speak to the business community's greater awareness of cyber threats and the catastrophic damage, both operational and financial, a cyberattack can have on a company," said Tim Francis, enterprise cyber lead at Travelers. "What's troubling is that while more businesses are securing cyber insurance as a tool to mitigate vulnerabilities, many still elect not to &#8212; despite knowing the risks."
According to the survey, medical cost inflation is the second-highest concern of business owners, with 59% saying that is what worries them the most. This is followed by increasing employee benefit costs and economic uncertainty at 59% and retaining talent at 54%.
Almost a quarter—24%—of 1,202 survey participants said their company had experienced a cyber incident, and more than half happened in the past year.
Read Also: <a href="https://www.benzinga.com/news/24/09/40791329/microsoft-plans-major-cybersecurity-summit-after-global-it-outage-hits-8-5m-devices-earlier-this-yea">Microsoft Plans Major Cybersecurity Summit After Global IT Outage Hits 8.5M Devices Earlier This Year</a>
This year&#8217;s survey marked the eighth time in nine years that the percentage of respondents who said their company has suffered a data breach or cyber event increased from the prior year.
Two-thirds of those surveyed said they had a cyber insurance policy, up from 60% of last year&#8217;s respondents and 39% of those polled in 2018.
The survey reported a year-over-year increase across businesses of all sizes: small businesses rose from 34% to 41%, mid-sized companies increased from 74% to 77%, and large businesses grew from 72% to 78%.
A security breach and someone gaining unauthorized access to financial accounts or control systems ranked as the type of cyber incident that most worried business owners at 57%. Ransomware caused 54% of respondents the most concern.
Employees causing risk through unsafe computing practices and a computer glitch worried 53% of respondents.
Price Action: Cybersecurity firms made gains and losses on Tuesday.
<ul>
<li>Telos Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) fell 3.09% to $3.45.</li>
<li>Zscaler, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) went up 0.37% to $174.15.</li>
<li>SentinelOne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) slipped 0.16% to $24.25.</li>
<li>CrowdStrike Holdings, Inc. (NASDSAQ: CRWD) declined 1.57% to $288.54.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/space/24/09/41013092/boeing-vs-spacex-will-stumbles-in-union-negotiations-space-travel-weaken-aerospace-giants-standing-">Boeing Vs. SpaceX: Will Stumbles In Union Negotiations, Space Travel Weaken Aerospace Giant&#8217;s Standing Against Elon Musk&#8217;s Company?</a></li>
</ul>
Photo: Shutterstock

Entertainment

Tech

General

CRWD

'Catastrophic Damage' From Cybersecurity Attacks Worries 62% Of Business Owners: Zscaler, CrowdStrike Stocks React

-Company Enters Note Purchase Agreement for up to $6.56 Million-
The Marygold Companies, Inc. ("TMC" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGLD#NYSE">MGLD</a>), a diversified global holding firm, today announced it has secured $4.38 million in funding as part of a $6.56 million total private placement with Streeterville Capital, LLC, an institutional investment firm, through the sale of the Company's secured promissory note.
Net proceeds will be used exclusively to implement next-stage initiatives for the Company's Marygold &amp; Co. project, including initial marketing of its recently developed fintech app., a digital platform alternative to traditional banking that enables users to spend, invest and save.

Financing

The Marygold Companies, Inc. Common Stock

MGLD

The Marygold Companies Secures For Up To $6.56M Private Placement To Finance Next-Stage Rollout Initiatives For Recently Developed Fintech Product

Stitch Fix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFIX#NASDAQ">SFIX</a>) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.19) by 52.63 percent. The company reported quarterly sales of $319.600 million which beat the analyst consensus estimate of $318.500 million by 0.35 percent. This is a 14.95 percent decrease over sales of $375.798 million the same period last year.

Earnings Misses

Stitch Fix Q4 2024 GAAP EPS $(0.29) Misses $(0.19) Estimate, Sales $319.600M Beat $318.500M Estimate

RITM

Rithm Capital Corp. Announces 30M Share Common Stock Offering

This order follows the successful completion of the advanced drone safety system customization project that the Company previously announced and marks another milestone for ParaZero in the growing air mobility sector.

Contracts

ParaZero Receives $187K Purchase Order From US-Based Advanced Air Mobility Company In The Aerial Vehicle Industry

JFBR

Jeffs' Brands shares are trading higher after the company announced the growth of its subsidiary Fort Product across Europe following its recent launch of commercialization of its products in multiple territories.

Taysha Gene Therapies GAAP EPS of -$0.09 beats by $0.01, revenue of $1.12M misses by $1.51M

Silvan Tuerkcan, an analyst from JMP Securities, maintained the Buy rating on Taysha Gene Therapies (TSHA – Research Report). The associated price ...

Buy Rating Justified by Taysha Gene Therapies' Clinical Advances and Extended Financial Runway

Jefferies analyst Maury Raycroft maintained a Buy rating on Taysha Gene Therapies (TSHA – Research Report) yesterday and set a price target of $8.0...

Buy Rating Affirmed for Taysha Gene Therapies Amid Strategic Planning and Potential Drug Efficacy

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amylyx Pharmaceuticals Inc (AMLX – Research Report...

Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Taysha Gene Therapies (TSHA) and Lexeo Therapeutics, Inc. (LXEO)

Geulah Livshits, an analyst from Chardan Capital, reiterated the Buy rating on Taysha Gene Therapies (TSHA – Research Report). The associated price...

Buy Rating Affirmed for Taysha Gene Therapies Amid Strong Financials and Promising Clinical Trials

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Beam Therapeutics (BEAM – Research Report) and Taysh...

Analysts Are Bullish on Top Healthcare Stocks: Beam Therapeutics (BEAM), Taysha Gene Therapies (TSHA)

Analyst Keith Tapper CFA of BMO Capital maintained a Buy rating on Taysha Gene Therapies (TSHA – Research Report), retaining the price target of $5...

Buy Rating for Taysha Gene Therapies Backed by Extended Cash Runway and Promising Trial Prospects

Canaccord Genuity analyst Whitney Ijem has maintained their bullish stance on TSHA stock, giving a Buy rating yesterday. Whitney Ijem has given his...

Maintained Buy Rating on Taysha Gene Therapies Amid Progress and Solid Financials

Truist Financial analyst Joon Lee maintained a Buy rating on Taysha Gene Therapies (TSHA – Research Report) today. The company's shares closed yest...

Truist Financial Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA)

BlackRock Health Sciences Term Trust Q2 2024 Commentary

ALNY

AMGN

AMLX

BEAM

BMEZ

IMCR

ISRG

LXEO

MRUS

NONOF

RHHBF

RHHBY

RHHVF

SARTF

SOAGY

SSSGY

SUVPF

UTHR

Press Releases

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Health Care

Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting

Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Taysha Gene Therapies to Release Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 12

Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Taysha Gene Therapies

Taysha Gene Therapies (TSHA) Forecast

Taysha Gene Therapies (NASDAQ:TSHA) Stock, Quote.Headers.trade-ideas